Expiry Dates and Date Marking on Nigerian Device Labels
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Nigeria imposes two layers of requirements on the time information on device labels: Regulation 17 requires the label to bear the expiry date, and Regulation 21 requires the label to bear the date marking, stating expressly that batch numbers and date marking shall not be pre-printed on the label but must be applied at the time of packaging.
This is the easiest point in Nigerian label compliance to get wrong by assumption. Many companies carry over European or American practice and pre-print the batch number and expiry in full on the carton, then apply a supplementary label batch by batch. In Nigeria, that treatment directly violates Regulation 21. The distinction between fixed artwork and variable data, which other markets tolerate, is here written into the law itself, so the packaging process — not only the artwork — becomes the compliance object.
A further, non-labelling but related practical threshold should be noted: NAFDAC laboratories may reject samples with less than 6 months of remaining shelf life at receipt. This is not a labelling provision, but it determines whether the batches you pre-print or code at packaging will actually pass into laboratory analysis for registration purposes. Planning teams that treat the two as separate calendars routinely discover the link only when a sample batch is turned away.
2. Legal basis
| Instrument | Reference number | Date | Provisions |
|---|---|---|---|
| NAFDAC Medical Devices and Related Products (Registration, Labelling and Advertisement) Regulations, 2024 | S.I. No. 42 of 2024 | 16 October 2024 | Regulation 17 (expiry date), Regulation 21 (date marking; batch numbers and date marking shall not be pre-printed), Regulation 16 (labelling information), Regulation 19 (product identification) |
| NAFDAC Medical Devices GMP Guidelines 2024 | DER-GDL-025-00 | Effective 11 November 2024 | §12.6 (UDI and packaging identification), §12.2 (label changes and records) |
| NAFDAC laboratory services page (sample acceptance and rejection) | No standalone number (NAFDAC website laboratory services page) | Current version | Grounds for sample rejection (less than 6 months remaining shelf life) |
| NAFDAC Guidelines for Registration of Medical Devices (Imported and Locally Manufactured) in Nigeria | R&R-GDL-008-02 | Effective 3 May 2024 | §7.0–§7.1.4 (documents accompanying laboratory analysis, including CoA) |
3. Expert insights
Insight one: the no-pre-printing rule targets batch numbers and date marking, not the whole label. Regulation 21 binds the batch number and the date marking — the two categories of information that change from batch to batch. Information that does not vary by batch, such as the brand name, the manufacturer’s name and address, composition, storage conditions and the NAFDAC registration number, may still be pre-printed. The accurate reading is: variable data is applied at packaging time; fixed information may be pre-printed. Companies should encode exactly this split in their packaging SOP so that no artwork revision or line change quietly reclassifies a variable field as fixed.
Insight two: why Nigeria writes the rule so strictly — anti-counterfeiting and traceability. Pre-printed batch numbers mean one print run can serve any batch, which in the distribution chain makes it easy to tamper with expiry dates or reuse batch numbers from conforming lots. Requiring batch numbers and date marking to be applied online at packaging (inkjet, thermal transfer or laser marking) physically binds the label to the specific batch, giving market sampling genuine traceability significance. The provision, Regulation 23 on the registration number and GMP §12.6 on UDI are three landing points of the same traceability logic, so investments in one area reinforce the others.
Insight three: the expiry date presentation must admit only one reading. Regulation 17 requires the expiry date to be stated but does not mandate a format. In practice we recommend year plus month with an explicit prefix (such as EXP or Use by), avoiding pure digit strings that can be read ambiguously between day/month/year and month/day/year orders. Imported products deserve particular care: the purely numeric formats common on origin-country labels may be treated as unclear marking during Nigerian market sampling. Changing the date presentation on the Nigeria-specific label costs little at artwork stage; changing it after a sampling finding is far more disruptive.
Insight four: shelf life and laboratory sample acceptance are linked, not separate matters. Among the NAFDAC laboratory rejection grounds is less than 6 months of remaining shelf life. This means the batch prepared for registration samples must be planned backwards from the moment of coding: the registration process itself takes 120 working days (R&R-GDL-008-02 §12.7) or 240 working days (VBM-R&RA-GDL-001-01 §11.7) under the two official reference points, and sample delivery is only one step within it. Short-shelf-life products (such as some IVD reagents) need a dedicated sampling batch freshness plan; otherwise the laboratory will return the samples on shelf-life grounds, and resampling lengthens the cycle again.
Insight five: changes to date marking connect to the label change procedure. Batch numbers and date marking are label content. If a company adjusts its coding rules or the coding position, this is a label change and must return to Regulation 6 to determine whether it is notifiable or requires prior approval — any change that may affect quality requires prior approval, and the holder must not distribute the product before the impact has been assessed and approved and the label has been revised. The rule catches seemingly innocuous moves, such as relocating the code to accommodate a new carton size.
4. Practical recommendations
- Establish an online coding station in the packaging process: apply batch number and expiry date on the packaging line, and prohibit full-plate pre-printing of these fields.
- State the variable information list in the packaging SOP: at minimum the batch number and expiry date; only fixed information may be pre-printed.
- Standardise the expiry format as year plus month with a prefix to avoid numeric ambiguity; check the English and other language versions together.
- Reserve shelf-life buffer for sample batches: plan sampling and shipment backwards from the official 6-month acceptance threshold.
- Validate and calibrate coding equipment, and bring coding records into the batch record to meet the GMP §12.2 labelling control requirements.
- Schedule sampling batches for short-shelf-life IVDs separately, never sharing one shipment plan with long-shelf-life devices.
These measures tie the label, the line and the registration timeline into one plan. The recurring failure pattern — a compliant label design defeated by an aged sample batch — is fully avoidable with a shared calendar owned jointly by regulatory and supply-chain staff.
5. Verification checklist
- □ The label bears the expiry date (Regulation 17).
- □ Batch numbers and date marking are not pre-printed but applied at packaging time (Regulation 21).
- □ The expiry date format is unambiguous (year plus month plus an explicit prefix).
- □ Sample batches have remaining shelf life ≥ 6 months (laboratory acceptance criterion).
- □ Coding equipment is validated and coding records are in the batch record (GMP §12.2).
- □ Changes to coding rules or positions have followed the Regulation 6 notification or prior approval procedure.
Regulatory information verified as of 29 October 2026. All content cited above was checked against the official Regulations (S.I. No. 42 of 2024, Regulations 16, 17, 19, 21, 23), the GMP guideline (DER-GDL-025-00 §12.2, §12.6) and R&R-GDL-008-02 (§7.0–§7.1.4); the 6-month remaining shelf life criterion derives from the sample rejection grounds on the NAFDAC laboratory services page and is a laboratory acceptance criterion, not a provision of the Regulations.
GRZAN supports manufacturers entering the Nigerian market with registration documentation and conformity files, including classification determination, registration pathway selection, technical documentation to the IMDRF ToC, GMP and foreign inspection readiness, advertisement permits, vigilance and PMS reporting, change management and renewal. Local resources in Nigeria cover licensed import entities and authorised representative services, NAPAMS online submission, dossier screening permit liaison, import permits, sample delivery and laboratory analysis support. Contact: hito.lin@grzan.cn; website www.grzan.cn.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us